[Form 4] Beta Bionics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), exercised employee stock options and completed an offsetting sale on 09/08/2025. He exercised 9,900 options with an exercise/conversion price of $5.10 per share, resulting in acquisition of 9,900 shares underlying the option.

The same day Mr. Feider sold 9,900 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $21.12648 per share (range $21.00–$21.2933). After these reported transactions he beneficially owned 44,041 shares of common stock and reported 89,695 derivative securities beneficially owned.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating pre-established compliance with insider trading rules
• Options exercised at $5.10 per share, creating realized value when sold at a much higher weighted average price
• Vesting schedule disclosed (48 equal monthly installments from 09/14/2023), providing transparency on option terms

Negative

• Insider sold 9,900 shares, which reduces direct insider ownership from 53,941 to 44,041 shares
• Reported sale price range ($21.00–$21.2933) shows shares were disposed of at market prices, potentially signaling partial liquidity-taking by management

Insights

Financial Analyst

TL;DR Insider exercised 9,900 options at $5.10 and sold the resulting shares under a 10b5-1 plan at a $21.13 weighted average.

The transaction is a routine exercise-and-sale by a named executive, reducing his direct common stock position from 53,941 to 44,041 shares after the trade. The exercise price of $5.10 and immediate sale at a weighted average of $21.12648 suggests a significant realized gain on the exercise itself. From an investor perspective, this is a liquidity and tax-management event rather than a disclosure of new information about company operations. The use of a pre-established Rule 10b5-1 plan indicates the sale followed an automated compliance framework.

Corporate Governance Expert

TL;DR Transaction followed a documented 10b5-1 plan and includes option vesting and exercise disclosures, consistent with governance best practices.

The filing discloses vesting terms for the exercised options (48 equal monthly installments from 09/14/2023) and cites a Rule 10b5-1 plan adopted 05/15/2025 for the sale. These disclosures are transparent and align with expected insider-trading controls. The simultaneous exercise and sale should be monitored for timing patterns, but the form shows adherence to procedural guardrails rather than ad hoc insider trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		M		9,900	A	$5.1	53,941	D
Common Stock	09/08/2025		S(1)		9,900	D	$21.1264(2)	44,041	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	09/08/2025		M			9,900	(3)	09/13/2033	Common Stock	9,900	$0	89,695	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

2. The weighted average sale price for the transaction reported was $21.126480 and the range of prices were between $21.00 and $21.2933. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics CFO Stephen Feider do on 09/08/2025 (BBNX)?

He exercised 9,900 employee stock options at an exercise price of $5.10 and sold 9,900 shares the same day under a Rule 10b5-1 plan at a weighted average price of $21.12648.

Was the sale by Stephen Feider part of a Rule 10b5-1 plan?

Yes. The shares sold on 09/08/2025 were sold pursuant to a Rule 10b5-1 plan adopted on May 15, 2025.

How many shares does Stephen Feider beneficially own after the transactions?

Following the reported transactions he beneficially owned 44,041 shares of common stock and reported 89,695 derivative securities beneficially owned.

At what prices were the shares sold and what was the sale range?

The weighted average sale price was $21.12648 and the reported range of prices was $21.00 to $21.2933.

What are the vesting terms for the exercised options?

The filing states the shares subject to the option vest in 48 equal monthly installments measured from 09/14/2023.